We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.

Delisted

RVNC was delisted on the 5th of February, 2025.

104 hedge funds and large institutions have $929M invested in Revance Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

417% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 6

165% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 17

117% more call options, than puts

Call options by funds: $5.64M | Put options by funds: $2.59M

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

44% more capital invested

Capital invested by funds: $644M → $929M (+$285M)

32% more funds holding

Funds holding: 79104 (+25)

Holders
104
Holders Change
+25
Holders Change %
+31.65%
% of All Funds
2.73%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
31
Increased
45
Reduced
17
Closed
6
Calls
$5.64M
Puts
$2.59M
Net Calls
+$3.04M
Net Calls Change
-$2.55M
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
101
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$366 +$7.28K +210 +2%
Jennison Associates
102
Jennison Associates
New York
-$2.33M -78,156 Closed
Fidelity International
103
Fidelity International
Bermuda
-$1.31M -44,064 Closed
IHM
104
Iguana Healthcare Management
New York
-$1.04M -35,000 Closed
William Blair & Company
105
William Blair & Company
Illinois
-$654K -22,007 Closed
NI
106
Numeric Investors
Massachusetts
-$330K -11,100 Closed
KF
107
Krilogy Financial
Missouri
-$3K -100 Closed
Walleye Trading
108
Walleye Trading
New York
+$139 +4 New
IA
109
IFP Advisors
Florida
+$243 +7 New
AssetMark Inc
110
AssetMark Inc
California
+$485 +14 New

RVNC Hedge Fund Activity: Q4 2015 in Review

104 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2015, worth a combined $929M — up 44% from $644M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new RVNC positions and 6 closed out — a net gain of 25 holders — while 45 added to existing stakes and 17 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $53.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.33M sold.

  • 104 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2015, up from 79 in Q3 2015.
  • Funds reported $929M of Revance Therapeutics, Inc. stock for Q4 2015, up 44% quarter-over-quarter.
  • 31 funds opened new Revance Therapeutics, Inc. positions in Q4 2015 and 6 closed out, a net change of +25 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2015 was JP Morgan Chase, an estimated $53.4M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2015 was Jennison Associates, an estimated $2.33M sold.

Based on aggregated 13F filings for Q4 2015.